BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 26279197)

  • 21. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
    Raj R; Frost AE
    J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.
    Zaffiri L; Long A; Neely ML; Cherikh WS; Chambers DC; Snyder LD
    J Heart Lung Transplant; 2020 Oct; 39(10):1089-1099. PubMed ID: 32654913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
    Boyle GJ; Michaels MG; Webber SA; Knisely AS; Kurland G; Cipriani LA; Griffith BP; Fricker FJ
    J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
    J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
    Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
    Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
    J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
    Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
    Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thoracic presentations of posttransplant lymphoproliferative disorders.
    Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA
    Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation.
    Kim IC; Kim SH; Youn JC; Kim D; Lee S; Kim H; Kim JJ; Jung MH; Rossano JW; Cherikh WS; Kobashigawa JA; Stehlik J
    JACC Heart Fail; 2024 Feb; 12(2):395-405. PubMed ID: 38326002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases.
    Paranjothi S; Yusen RD; Kraus MD; Lynch JP; Patterson GA; Trulock EP
    J Heart Lung Transplant; 2001 Oct; 20(10):1054-63. PubMed ID: 11595560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
    Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J
    J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.